Group 1 - The recent promotion by Qianwen App allowing users to purchase milk tea for 0.01 yuan signifies a pivotal moment for AI applications in China, moving from simple chat functions to actionable tasks [1] - OpenClaw, an open-source AI agent, has gained rapid popularity among developers, indicating a shift in AI applications towards more practical uses [2] - Investment analysts are optimistic about AI as a key market trend, with expectations for significant technological breakthroughs in AI multimodal applications and biomedical fields over the next few years [2][3] Group 2 - The emergence of "AI-native super applications" like LiblibAI is anticipated to create benchmark cases of user growth and revenue by 2026 [3] - The AI application market is transitioning from infrastructure investment to commercial value realization, with a focus on cash-generating applications in the downstream sector [3] - Hardware innovations in smartphones, cars, and smart home devices are expected to drive sustainable industry trends, with companies like Apple leading the charge [3] Group 3 - The field of embodied intelligence, particularly humanoid robots, is gaining attention, with expectations for significant advancements in 2026 [4] - Major robotics companies are collaborating with the 2026 CCTV Spring Festival Gala, showcasing the potential for humanoid robots to perform real-world tasks [4] - Breakthroughs in action models for humanoid robots are predicted to enhance their operational capabilities in unstructured environments [5] Group 4 - The commercial space sector is identified as a significant growth area, with expectations for a pivotal moment in 2026 when SpaceX is projected to go public [6] - Chinese commercial space companies are likely to successfully implement rocket recovery operations, marking a significant milestone for the industry [6] - The low Earth orbit satellite internet sector is entering a phase of industrial explosion, with a ten-year growth cycle anticipated [6][7] Group 5 - The rocket segment is under scrutiny due to its potential to address capacity bottlenecks and high costs, with a focus on companies that can successfully reduce costs [7] - The satellite operations market is viewed as a scarce resource, with significant potential for growth in traditional high-end markets and emerging low-altitude economies [7] - The concept of space computing, utilizing AI data centers in space, is being explored as a revolutionary approach to energy and computational efficiency [7] Group 6 - The 14th Five-Year Plan emphasizes the importance of quantum technology, biomanufacturing, hydrogen energy, and other advanced fields as new economic growth points [9] - Key technological breakthroughs in areas like quantum computing and brain-machine interfaces are expected to occur by 2026, significantly impacting market confidence [9][10] - The Chinese pharmaceutical industry is poised for a breakthrough in global drug development, with several companies expected to achieve significant clinical trial results in 2026 [10] Group 7 - AI-driven drug development is anticipated to reach a validation point in 2026, showcasing the potential of AI in creating tangible medical solutions [10] - The brain-machine interface sector is expected to achieve clinical breakthroughs, particularly in flexible electrodes and signal processing chips [10] - Investment strategies are shifting towards companies that can effectively translate technological innovations into commercial success, moving away from resource accumulation [11]

Macro and Strategy Research - In January 2026, the central bank's liquidity net injection reached 1.2 trillion yuan, an increase of nearly 400 billion yuan compared to December 2025, indicating a supportive stance on liquidity [3] - The issuance of interest rate bonds in January 2026 totaled 2.7 trillion yuan, a year-on-year increase of over 600 billion yuan, with significant growth in government bonds, local bonds, and policy financial bonds [4] - The bond market outlook suggests that if the liquidity remains stable, interest rate bonds may show a strong oscillation pattern, with a focus on 3-year bonds and ultra-long-term bonds for potential gains [5] Industry Research - The pharmaceutical and biotechnology industry is seeing a concentration of performance forecasts, with key developments including the approval of new drugs and significant partnerships among companies [10][11] - The SW pharmaceutical and biotechnology index saw a decline of 0.97% in the week of January 30 to February 5, 2026, with the industry’s price-to-earnings ratio at 51.01 times, reflecting a 261% premium over the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, as well as monitoring companies that are expected to show a turnaround in performance [12]

中国创新药正步入全面收获期。在刚刚过去的2025年，我国生物医药产业创新活力迸发——全年76个创 新药获批，国产占比超八成；对外授权交易总额突破1300亿美元，创历史新高。 以仿制药起家，到转型创新药，"药王"恒瑞医药（600276）(600276.SH、01276.HK)的发展历程堪称是 中国医药产业升级的缩影。从以仿制药为营收支柱，到创新药收入占比突破60%，复出五年，孙飘扬带 领恒瑞医药转型攻坚，通过持续创新、差异化与国际化破局行业"内卷"。 2026年2月1日，恒瑞医药第九届董事会任期届满，68岁的孙飘扬会否继续担任董事长一职？恒瑞医药的 创新药全球化征程会走向怎样的新高度？ 仿制药巨头大象转身 将时间拨回2020年，那一年，恒瑞医药以超6100亿元的市值傲视群雄，稳坐A股"医药一哥"。当年，恒 瑞医药的营业收入和归母净利润分别达到277.35亿元、63.28亿元的高峰。当年，在执掌恒瑞医药近三十 年后，孙飘扬决定退居幕后，将恒瑞交给职业经理人团队。 也是在那一年，国家药品集采政策全面实施，宣告着仿制药的高利润时代终结。以仿制药起家的恒瑞医 药危机悄然浮现。 随着集采不断扩围，市场被蚕食，2021年， ...

医药周报 20260208: 【国联民生医药】小核酸风口之上：四重催化密集 glmszqdatemark 医药行情回顾&分析&近期判断 行情回顾：当周（2.2-2.6）医药生物指数环比 0.14%，跑赢创业板指数和沪深 300 指数。在所有行业中，当周（2.2-2.6）医药涨跌幅排在第 14 位。医药在周一大 跌后，本周后面都是在演绎修复。结构上看，创新链条，A 股部分辨识度个股表 现不错，CRO 及部分上游条线表现较好。非创新药方面，消费医疗、中药也有一 定表现，表现从创新聚焦开始发散。医药成交总额 4755.06 亿元，沪深总成交额 为 119319.07 亿元，医药成交额占比沪深总成交额比例为 3.99%（2013 年以来 成交额均值为 7.09%）。 原因分析：医药整体不在市场重心，仍然是散点行情为主，同时内部切换特征也 比较明显，创新条线走发散逻辑，CRO 及部分上游表现较好。非创新药方面，受 市场整体消费表现较好带动，消费医疗部分表现相对较强，中药因政策刺激周五 表现较好，在行业普遍表现一般的状态下相对表现较好。近期重磅 BD，从走势反 馈角度，还在消化筹码，产业逻辑依旧强劲，核心标的逐步进入价值 ...

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

Core Viewpoint - The pharmaceutical retail market is transitioning towards high-quality development, with significant growth opportunities anticipated in various segments, including traditional Chinese medicine, medical devices, and innovative drugs [17][22][46]. Market Overview - The retail scale of China's physical pharmacies for January to November 2025 is projected to reach 557.7 billion yuan, showing a slight year-on-year decline of 0.8%. However, the cumulative scale for October and November is expected to be 108.7 billion yuan, reflecting a year-on-year growth of 4.0% [22][30]. - The pharmaceutical retail market is experiencing a recovery phase, driven by ongoing healthcare reforms and the optimization of market structures, which are expected to enhance the industry's long-term growth prospects [22][30]. Category Analysis - **Pharmaceuticals**: The cumulative scale for pharmaceuticals from January to November 2025 is estimated at 453.4 billion yuan, with a year-on-year growth of 0.4%. The sales scale for October and November is projected to be 88 billion yuan, with a year-on-year increase of 5.5% [29]. - **Traditional Chinese Medicine (TCM)**: The cumulative scale for TCM from January to November 2025 is expected to be 42.9 billion yuan, reflecting a year-on-year decline of 4.2%. However, November shows a month-on-month growth of 12.5% [30]. - **Medical Devices**: The cumulative scale for medical devices is projected to be 26.1 billion yuan, with a slight year-on-year decline of 0.4%. The sales scale for October and November is expected to show a year-on-year growth of 6.3% [37]. - **Health Products**: The cumulative scale for health products is anticipated to be 21 billion yuan, with a year-on-year decline of 15.7%. However, November shows signs of recovery with a month-on-month growth of 5.3% [34]. Investment Opportunities - The pharmaceutical sector is expected to benefit from a low valuation environment, with public funds showing low allocation to the sector. The anticipated recovery in macroeconomic factors and the demand for major products are expected to drive growth in the industry [15]. - The innovative drug sector is transitioning from quantity to quality, with a focus on differentiated products and internationalization. Companies with strong pipelines and the ability to deliver profits are recommended for investment [15][46]. - The medical device market is witnessing a recovery in bidding volumes, with ongoing updates and international expansion opportunities. Companies focusing on innovation and product upgrades are expected to perform well [46]. Specific Product Trends - **Top Chemical Drugs**: In October and November 2025, the top 20 chemical drug categories accounted for 78.3% and 80.0% of the market share, respectively, with significant growth in categories such as anti-tumor drugs and systemic antiviral drugs [40][41]. - **Top Traditional Chinese Medicine Products**: The market share for TCM in November reached 86.4%, with notable growth in cold medications and cough remedies [44][45]. Conclusion - The pharmaceutical retail market is poised for a significant transformation, with various segments showing potential for growth. The ongoing reforms and market dynamics are expected to create a favorable environment for investment in the pharmaceutical and healthcare sectors [22][30][46].

Core Viewpoint - The company forecasts a product revenue of approximately 11.9 billion yuan for 2025, representing a year-on-year growth of about 45%, with Q4 revenue expected to reach around 3.3 billion yuan, showing over 60% growth year-on-year, aligning with expectations [1] Group 1: Revenue Growth and Product Expansion - The company's product revenue is set to surpass 10 billion yuan for the first time, driven by innovative products [1] - By 2025, the company's oncology product portfolio has expanded to 13 products, with the revenue from the drug Sintilimab expected to be 551 million USD, reflecting a year-on-year growth of approximately 5% [1] - Several potential blockbuster products are anticipated to be approved for market launch in 2025, including Masitinib, Tislelizumab, and Pidilizumab, which are expected to contribute significantly to the company's revenue growth [1] Group 2: New Products and Future Performance - Seven products, including Sintilimab and Tislelizumab, have been added to the national medical insurance directory for 2025, effective from 2026, indicating clear performance drivers for 2026 [2] - The company is expected to focus on the continuous development of innovative molecules like IBI363 and its internationalization process in 2026, with a significant collaboration with Takeda worth 10 billion USD announced in October 2025 [2] - The completion of the collaboration and share transfer with Takeda is anticipated to significantly enhance profits in 2026 [2] Group 3: Profit Forecast and Valuation - The revenue forecast for 2025 has been raised by 5.0% to 12.6 billion yuan, while the net profit forecast for 2026 has been increased by 274% to 6.68 billion yuan, with a new forecast for 2027 net profit set at 4.14 billion yuan [2] - The company maintains an outperform rating, with a target price of 118.3 HKD, indicating a potential upside of 48.06% from the current stock price [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (21.3% growth) - 2025E: RMB 15,426 million (25.8% growth) - 2026E: RMB 15,600 million (1.1% growth) - 2027E: RMB 17,644 million (13.1% growth) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (33.4% growth) - 2025E: RMB 5,434 million (24.3% growth) - 2026E: RMB 4,739 million (-12.8% decline) - 2027E: RMB 5,828 million (23.0% growth) [6][12]. - The company’s earnings per share (EPS) are projected to be: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12]. Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting the company's growth potential despite an upward revision in sales expense forecasts [4][7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (growth rate of 21.3%) - 2025E: RMB 15,426 million (growth rate of 25.8%) - 2026E: RMB 15,600 million (growth rate of 1.1%) - 2027E: RMB 17,644 million (growth rate of 13.1%) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (growth rate of 33.4%) - 2025E: RMB 5,434 million (growth rate of 24.3%) - 2026E: RMB 4,739 million (decline of 12.8%) - 2027E: RMB 5,828 million (growth rate of 23.0%) [6][12] - The company’s earnings per share (EPS) projections are: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12] Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting a potential upside from the current price of HKD 36.62 [4][7].

Group 1 - The core viewpoint of the article highlights the recovery of clinical CRO demand due to the rebound in innovative drug financing and R&D activities, regulatory emphasis on efficiency, and the transition to data-driven and intelligent clinical execution models [1] Group 2 - Innovative drug financing and BD (business development) activities have shown a synchronized recovery, with the primary market financing amount in the healthcare sector reaching approximately 79.5 billion yuan from Q1 to Q3 of 2025, representing a year-on-year increase of 22%. This shift indicates a move from "early and small investments" to "clinical and certainty-based investments" [1] - The scale of Chinese innovative drug BD activities abroad reached a historical high, with a total transaction amount of approximately 135.7 billion USD and upfront payments of about 7 billion USD for the year [1] Group 3 - The number of IND (Investigational New Drug) applications has continued to rise, with the CDE (Center for Drug Evaluation) accepting 1,878 INDs in 2025, a year-on-year increase of 13.3%. The proportion of Class 1 innovative drugs has increased to 1,517 varieties, indicating a concentration of R&D resources on high clinical value innovative projects [2] - Approval rates for Class 1 innovative drug INDs are approximately 96.5%, while NDA (New Drug Application) approval rates are around 86.9%, reflecting improved review efficiency and approval rates [2] Group 4 - The global regulatory focus has shifted from "risk avoidance" to "efficiency first," which is expected to accelerate clinical trial timelines. The FDA has prioritized enhancing R&D and review efficiency, including streamlining clinical initiation processes and allowing more dynamic data usage [2] Group 5 - Clinical trials are evolving towards data-driven and continuous processes, with a shift from "phase-based advancement" to "process management and data-driven" approaches. This evolution requires CROs to extend their capabilities beyond mere execution to include data collection, quality control, statistical analysis, and IT system capabilities [3] - The implementation of continuous trial designs, real-time data monitoring, and phase-based submissions is becoming more common, enhancing the efficiency of clinical execution [3] - Leading CROs with digital platforms, compliance systems, and scale advantages are better positioned to translate technological capabilities into execution efficiency, thereby reflecting higher certainty during the recovery phase [3]